Thrombolex, Inc. specializes in the development of advanced medical devices for the treatment of arterial and venous thromboembolic conditions, primarily through their innovative BASHIR™ Family of Endovascular Catheters. These catheters utilize a unique hybrid mechanism that combines mechanical and pharmacological therapies to optimize thrombus resolution. The design features an expandable infusion basket that allows for targeted delivery of thrombolytics, facilitating immediate restoration of blood flow. This mechanism not only enhances the efficiency of thrombus lysis but also minimizes risks associated with traditional treatment methods, thereby aiming to improve clinical outcomes for patients suffering from conditions such as pulmonary embolism and extensive thrombus burden.

The BASHIR™ catheters are engineered to create fissures in the thrombus through mechanical expansion, which increases the surface area exposed to both endogenous and exogenous thrombolytics. This dual approach promotes a synergistic effect that accelerates the lysis of clots. The catheters are available in various sizes and configurations, including options specifically designed for navigating shorter and more tortuous vessels. By leveraging advanced design features such as nitinol-enhanced infusion baskets and multiple infusion channels, Thrombolex aims to set a new standard of care in the treatment of thromboembolic diseases, ensuring both safety and efficacy in clinical applications.

United States

Thrombolex is engaged in the design, development, and distribution of innovative endovascular catheters used in interventional procedures, particularly in pharmaco-mechanical catheter-directed thrombolysis (PM-CDT) in patients who suffer from arterial and venous thromboembolic (A&VTE) conditions. The Company is currently marketing seven (7) different FDA-cleared devices that are all based on the BASHIR™ Endovascular Catheter platform technology.

Thrombolex, Inc.

Company Details